Activated F IX Concentrate (FEIBA) Used in the Treatment of Haemophilic Patients with Antibody to F VIII
- 12 January 1978
- journal article
- research article
- Published by Wiley in Acta Medica Scandinavica
- Vol. 203 (1-6), 471-476
- https://doi.org/10.1111/j.0954-6820.1978.tb14910.x
Abstract
Bleeding episodes in 5 hemophiliacs with antibody to F [factor] VIII were treated by activated F IX concentrate (FEIBA [F VIII inhibitor bypassing activity]). Relief of pain and hemostasis in affected muscles and joints were recorded in each case. One patient developed a mild attack of disseminated intravascular coagulation with an uneventful recovery. A substantial rise in natural inhibitors of coagulation was seen in 2 patients, and all but 1 experienced a rise in F VIII antibody titer.This publication has 12 references indexed in Scilit:
- FACTOR VIII INHIBITOR BYPASSING ACTIVITYThe Lancet, 1976
- FACTOR-VIII INHIBITOR BYPASSING ACTIVITYThe Lancet, 1976
- TRAUMATIC RUPTURE OF THE LIVER IN A HqMOPHILIAC PATIENT WITH FACTOR-VIII INHIBITORSThe Lancet, 1976
- Immunosuppressive Treatment in Haemophiliacs with Inhibitors to Factor VIII and Factor IXScandinavian Journal of Haematology, 1976
- Acquired Thrombophilia: A Hitherto Unrecognized Procoagulant‐Antithrombin ImbalanceScandinavian Journal of Haematology, 1976
- Treatment of life-threatening hemorrhage due to acquired factor VIII inhibitorBlood, 1975
- A Circulating Factor V Inhibitor: Possible Side Effect of Treatment with StreptomycinScandinavian Journal of Haematology, 1975
- Activated Prothrombin Concentrate for Patients with Factor VIII InhibitorsNew England Journal of Medicine, 1974
- Antithrombin III, Antifactor Xa and HeparinBritish Journal of Haematology, 1970
- On an Inherited Autosomal Hemorrhagic Diathesis with Antihemophilic Globulin (AHG) Deficiency and Prolonged Bleeding Times1Acta Medica Scandinavica, 1957